Indication
Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma
1 clinical trial
8 products
1 drug
Clinical trial
A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)Status: Completed, Estimated PCD: 2021-03-31
Product
Brentuximab VedotinProduct
CrizotinibDrug
cyclophosphamideProduct
CytarabineProduct
DexamethasoneProduct
DoxorubicinProduct
EtoposideProduct
IfosfamideProduct
Methotrexate